tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Fate Therapeutics Inc (FATE)
:FATE
US Market
FATE
Fate Therapeutics
Overview
Analyst Forecasts
AI Stock Analysis
News & Insights
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Historical Prices
Stock Buybacks
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Fate Therapeutics (FATE) Stock Forecast & Price Target

Compare
1,168 Followers
See the Price Targets and Ratings of:

FATE Analyst Ratings

Moderate Buy
12Ratings
4 Buy
8 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Fate
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FATE Stock 12 Month Forecast

Average Price Target

$6.17
▲(601.14% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is $6.17 with a high forecast of $12.00 and a low forecast of $2.50. The average price target represents a 601.14% change from the last price of $0.88.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Dec<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.956923076923077,2.793846153846154,3.6307692307692307,4.467692307692308,5.304615384615384,6.141538461538461,6.978461538461539,7.815384615384615,8.65230769230769,9.489230769230769,10.326153846153847,11.163076923076922,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.5084615384615385,1.896923076923077,2.285384615384616,2.6738461538461538,3.0623076923076926,3.450769230769231,3.8392307692307694,4.227692307692308,4.616153846153846,5.004615384615384,5.393076923076923,5.781538461538462,{"y":6.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.12,1.2261538461538461,1.3323076923076924,1.4384615384615385,1.5446153846153847,1.6507692307692308,1.7569230769230768,1.863076923076923,1.9692307692307693,2.0753846153846154,2.1815384615384614,2.287692307692308,2.3938461538461535,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.93,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$12.00Average Price Target$6.17Lowest Price Target$2.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
xxxxxxxxxxxxxxxxxx
TD Cowen
TD Cowen
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/12/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bank of America Securities
Bank of America Securities
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Wedbush
Wedbush
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Jefferies
Jefferies
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Morgan Stanley
Morgan Stanley
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Wells Fargo
Wells Fargo
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Barclays
Barclays
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Stifel Nicolaus
Stifel Nicolaus
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Oppenheimer
Oppenheimer
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Needham
Needham
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Piper Sandler Analyst forecast on FATE
Edward Tenthoff
Piper Sandler
$6
Buy
581.82%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and Elicio Therapeutics (NASDAQ: ELTX)
Leerink Partners Analyst forecast on FATE
Daina Graybosch
Leerink Partners
$12
Buy
1263.64%
Upside
Reiterated
03/06/25
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
Robert W. Baird Analyst forecast on FATE
Jack Allen
Robert W. Baird
$5
Hold
468.18%
Upside
Reiterated
11/13/24
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Fate Therapeutics (NASDAQ: FATE)
H.C. Wainwright Analyst forecast on FATE
Robert Burns
H.C. Wainwright
$5
Hold
468.18%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Citi Analyst forecast on FATE
Yigal Nochomovitz
Citi
$10
Buy
1036.36%
Upside
Reiterated
05/15/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), Acumen Pharmaceuticals (NASDAQ: ABOS) and DENTSPLY SIRONA (NASDAQ: XRAY)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
xxxxxxxxxxxxxxxxxx
TD Cowen
TD Cowen
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/12/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Bank of America Securities
Bank of America Securities
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/07/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Wedbush
Wedbush
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Jefferies
Jefferies
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Morgan Stanley
Morgan Stanley
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Wells Fargo
Wells Fargo
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Barclays
Barclays
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Stifel Nicolaus
Stifel Nicolaus
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Oppenheimer
Oppenheimer
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxx
Needham
Needham
xxxxxxxxxxxxx
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Reiterated
03/06/25
xxxxxxxxxxxxx
xxxxxxxxxxxxx
Piper Sandler Analyst forecast on FATE
Edward Tenthoff
Piper Sandler
$6
Buy
581.82%
Upside
Reiterated
03/06/25
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (NASDAQ: FATE), ALX Oncology Holdings (NASDAQ: ALXO) and Elicio Therapeutics (NASDAQ: ELTX)
Leerink Partners Analyst forecast on FATE
Daina Graybosch
Leerink Partners
$12
Buy
1263.64%
Upside
Reiterated
03/06/25
Optimistic Outlook for Fate Therapeutics' FT819 in Cell-Therapy Space Amid Promising Phase 1 Results
Robert W. Baird Analyst forecast on FATE
Jack Allen
Robert W. Baird
$5
Hold
468.18%
Upside
Reiterated
11/13/24
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE), Mereo Biopharma Group Plc (NASDAQ: MREO) and Fate Therapeutics (NASDAQ: FATE)
H.C. Wainwright Analyst forecast on FATE
Robert Burns
H.C. Wainwright
$5
Hold
468.18%
Upside
Reiterated
08/22/24
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Fate Therapeutics (NASDAQ: FATE)
Citi Analyst forecast on FATE
Yigal Nochomovitz
Citi
$10
Buy
1036.36%
Upside
Reiterated
05/15/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), Acumen Pharmaceuticals (NASDAQ: ABOS) and DENTSPLY SIRONA (NASDAQ: XRAY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FATE Analyst Recommendation Trends

Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
6
7
6
4
6
Buy
3
3
2
0
0
Hold
21
23
14
2
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
33
22
6
15
In the current month, FATE has received 6 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. FATE average Analyst price target in the past 3 months is $6.17.
Each month's total comprises the sum of three months' worth of ratings.

FATE Financial Forecast

FATE Earnings Forecast

Next quarter’s earnings estimate for FATE is -$0.39 with a range of -$0.45 to -$0.28. The previous quarter’s EPS was -$0.44. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s earnings estimate for FATE is -$0.39 with a range of -$0.45 to -$0.28. The previous quarter’s EPS was -$0.44. FATE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Sales Forecast

Next quarter’s sales forecast for FATE is $969.00K with a range of $0.00 to $3.40M. The previous quarter’s sales results were $1.86M. FATE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.38% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.
Next quarter’s sales forecast for FATE is $969.00K with a range of $0.00 to $3.40M. The previous quarter’s sales results were $1.86M. FATE beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.38% of the time in the same period. In the last calendar year FATE has Outperformed its overall industry.

FATE Stock Forecast FAQ

What is FATE’s average 12-month price target, according to analysts?
Based on analyst ratings, Fate Therapeutics Inc’s 12-month average price target is $6.17.
    What is FATE’s upside potential, based on the analysts’ average price target?
    Fate Therapeutics Inc has 601.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FATE a Buy, Sell or Hold?
          Fate Therapeutics Inc has a consensus rating of Moderate Buy which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.
            What is Fate Therapeutics Inc’s price target?
            The average price target for Fate Therapeutics Inc is $6.17. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $12.00 ,the lowest forecast is $2.50. The average price target represents 601.14% Increase from the current price of $0.88.
              What do analysts say about Fate Therapeutics Inc?
              Fate Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of FATE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

                  Become an Expert with TipRanks Premium

                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis
                  Subscribe NowSee Plans & Pricing